Affibody Progresses Lead Asset To Phase II in Uveitis
IL-17 blocker izokibep targets autoimmune diseases
The FDA has cleared the novel interleukin-17 blocker izokibep (ABY-035) to proceed to Phase II clinical development in non-infectious intermediate, posterior and pan-uveitis.
You may also be interested in...
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.